Latest Healthcare News

Adherium Limited reports a robust 30% increase in US remote patient monitoring users and closes a $4.5 million capital raise, positioning itself for accelerated growth under new leadership.

Oakridge International reported robust revenue growth and expanded its partner network in Q4 2025, underpinning a promising outlook in healthcare technology. The company also advanced product innovation aligned with new industry standards.

Gathid Ltd reported a robust 14% quarterly increase in Annual Recurring Revenue to $1.936 million, driven by new customer wins and expansions, even as a legal dispute over its physical security business sale remains unresolved.

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

IMEXHS Limited reported steady Q2 FY25 revenue with an 11% rise in annual recurring revenue, supported by a $2.6 million capital raise and operational advances including a major Mexican contract win.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Hydrix Limited reports steady June quarter revenues with a 10% rise from the prior quarter, supported by new contract wins and a robust $40 million project pipeline.

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

Micro-X has landed a significant supply agreement with a top US healthcare provider for its Rover Plus mobile X-ray units, while progressing clinical trials and development milestones for its innovative CT imaging products.

Doctor Care Anywhere has reported a landmark positive operating and investing cash inflow in Q2 2025, alongside modest consultation growth and strategic service expansion. The company reiterates its ambitious revenue and profitability targets amid ongoing cost transformation.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.